Sema6A and Mical1 control cell growth and survival of BRAFV600E human melanoma cells

Oncotarget

Volumn 6, Issue 5, 2015, Pages 2779-2793

  Loria, Rossella ^a   Bon, Giulia ^a   Perotti, Valentina ^b   Gallo, Enzo ^a   Bersani, Ilaria ^b   Baldassari, Paola ^b   Porru, Manuela ^a   Leonetti, Carlo ^a   Carlo, Selene Di ^a   Visca, Paolo ^a   Brizzi, Maria Felice ^c   Anichini, Andrea ^b   Mortarini, Roberta ^b   Falcioni, Rita ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

BRAFV600E melanoma; Cell survival; Mical1; NRASQ61R melanoma; Sema6A

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR 3; MESSENGER RNA; MICAL1 PROTEIN; NDR PROTEIN KINASE; OXIDOREDUCTASE; PLEXIN; PLEXINA2; PLEXINA4; PROTEIN KINASE; SEMA6A PROTEIN; SEMAPHORIN; UNCLASSIFIED DRUG; BRAF PROTEIN, HUMAN; CYTOSKELETON PROTEIN; HEMGN PROTEIN, HUMAN; LIM PROTEIN; MICAL1 PROTEIN, HUMAN; NUCLEAR PROTEIN; SEMA6A PROTEIN, HUMAN; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE METASTASIS; BRAF GENE; CANCER GROWTH; CELL DEATH; CELL INVASION; CELL MOTILITY; CELL SURVIVAL; CHEMOTAXIS; CONTROLLED STUDY; CUTANEOUS MELANOMA; CYTOSKELETON; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; LYMPH NODE METASTASIS; MALE; MELANOMA CELL; METASTASIS POTENTIAL; METASTATIC MELANOMA; MICAL1 GENE; MICROARRAY ANALYSIS; MOUSE; NEVUS; NONHUMAN; ONCOGENE N RAS; PROTEIN PHOSPHORYLATION; SEMA6A GENE; STRESS FIBER; TUMOR INVASION; ACTIN FILAMENT; ANIMAL; CELL ADHESION; CELL MOTION; CELL PROLIFERATION; DNA MICROARRAY; ENZYMOLOGY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; GENETIC TRANSFECTION; GENETICS; IMMUNOHISTOCHEMISTRY; MELANOMA; METABOLISM; MUTATION; NUDE MOUSE; PATHOLOGY; PHOSPHORYLATION; PROCEDURES; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SKIN TUMOR; TUMOR CELL LINE; WESTERN BLOTTING;

ACTIN CYTOSKELETON; ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CYTOSKELETAL PROTEINS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC ASSOCIATION STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; LIM DOMAIN PROTEINS; MALE; MELANOMA; MICE, NUDE; MUTATION; NEOPLASM INVASIVENESS; NUCLEAR PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS B-RAF; REAL-TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SEMAPHORINS; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TRANSFECTION;

EID: 85044692107     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature. 2007; 445: 851-7.
2. Chapman PB, Hauschild A, Robert C, Haanen JB Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutations. N Engl J Med. 2011; 364: 2507-16.
3. Menzies AM, Long GV. Dabrafenib and Trametinib, Alone and in Combination for BRAF-Mutant Metastatic Melanoma. Clin Cancer Res. 2014; 20: 2035-43.
4. Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, Chodon T, Guo R, Johnson DB, Dahlman KB, Kelley MC, Kefford RF, Chmielowski B, et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitory therapy. Cancer Discov. 2014; 4: 80-93.
5. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, Chodon T, Nelson SF, McArthur G, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010; 468: 973-7.
6. Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, Shi H, Arefi M, Titz B, Gabay MT, Salton M, Dahlman KB, Tadi M, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature. 2011; 480: 387-90.
7. Wangle N, Van Allen EM, Treacy DJ, Frederick DT, Cooper ZA, Taylor-Weiner A, Rosenberg M, Goetz EM, Sullivan RJ, Farlow DN, Friedrich DC, Anderka K, Perrin D, et al. Map kinase pathway alteration in BRAF-mutant melanoma patient with acquired resistance to combined RAF/MEK inhibition. Cancer Discov. 2014; 4: 61-80.
8. Shi H, Hong A, Kong X, Koya RC, Song C, Moriceau G, Hugo W, Yu CC, Ng C, Chodon T, Scolyer RA, Kefford RF, Ribas A, et al. A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. Cancer Discov. 2014; 4: 69-79.
9. Van Allen EM, Wagle M, Sucker A, Treacy DJ, Johannessen CM, Goetz EM, Place CS, Taylor-Weiner A, Whittaker S, Kryukov GV, Hodis E, Rosenberg M, McKenna A, et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov. 2014; 4: 94-109.
10. Reschke M, Mihic-Probst D, vad der Horst EH, Knyazev P, Wild PJ, Hutterer M, Meyer S, Dummer R, Moch H, Ullrich A. HER3 is a determinant for poor prognosis in melanoma. Clin Cancer Res. 2008; 14: 5188-97.
11. Chakrabarty A, Sánchez V, Kuba MG, Rinehart C, Arteaga CL. Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitor. Proc Natl Acad Sci U S A. 2012; 109: 2718-23.
12. Greaves WO, Verma S, Patel KB, Davies MA, Barkoh BA, Galbincea JM, Yao H, Lazar AJ, Aldape KD, Medeiros LJ, Luthra R. Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma. J Mol Diagn. 2013; 15: 220-6.
13. Mann GJ, Pupo GM, Campain AE, Carter CD, Schramm SJ, Pianova S, Gerega SK, De Silva C, Lai K, Wilmott JS, Synnott M, Hersey P, Kefford RF. BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma. J Invst Dermatol. 2013; 133: 509-17.
14. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, Cho KH, Aiba S, Bröcker EB, LeBoit PE, Pinkel D, Bastian BC. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005; 353: 2135-47.
15. Bloethner S, Chen B, Hemminki K, Müller-Berghaus J, Ugurel S, Schadendorf D, Kumar R. Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines. Carcinogenesis. 2005; 26: 1224-32.
16. Pavey S, Johansson P, Packer L, Taylor J, Stark M, Pollock PM, Walker GJ, Boyle GM, Harper U, Cozzi SJ, Hansen K, Yudt L, Schmidt C. Microarray expression profiling in melanoma reveals a BRAF mutations signature. Oncogene. 2004; 23: 4060-7.
17. Hoek KS, Schlegel NC, Brafford P, Sucker A, Ugurel S, Kumar R, Weber BL, Nathanson KL, Phillips DJ, Herlyn M, Schadendorf D, Dummer R. Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res. 2006; 19: 290-302.
18. Johansson P, Pavey S, Hayward N. Confirmation of a BRAF mutation-associated gene expression signature in melanoma. Pigment Cell Res. 2007; 20: 216-21.
19. Ellerhorst JA, Greene VR, Ekmekcioglu S, Warneke CL, Johnson MM, Cooke CP, Wang LF, Prieto VG, Gershenwald JE, Wei Q, Grimm EA. Clinical correlation of NRAS and BRAF mutations in primary human melanoma. Clin Cancer Res. 2011; 17: 229-35.
20. Sensi M, Nicolini G, Petti C, Bersani I, Lozupone F, Molla A, Vegetti C, Nonaka D, Mortarini R, Parmiani G, Fais S, Anichini A. Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma. Oncogene. 2006; 25: 3357-64.
21. Neufeld G, Kessler O. The semaphorins: versatile regulators of tumour progression and tumour angiogenesis. Nat Rev Cancer. 2008; 8: 632-45.
22. Segarra M, Ohnuki H, Maric D, Salvucci O, Hou X, Kumar A, Li X, Tosato G. Semaphorin 6A regulates angiogenesis by modulating VEGF signaling. Blood. 2012; 120: 4105-15.
23. Renaud J, Kerjan G, Sumita I, Zagar Y, Georget V, Kim D, Fouquet C, Suda K, Sanbo M, Suto F, Ackerman SL, Mitchell KJ, FujisawaH, et al. Plexin-A2 and its ligand, Sema6A, control nucleus-centrosome coupling in migrating granule cells. Net Neurosci. 2008; 11: 440-9.
24. Cabodi S, del Pilar Camacho-Leal M, Di Stefano P, Defilippi P. Integrin signalling adaptors: not only figurants in the cancer story. Nat Rev Cancer. 2010; 10: 858-70.
25. Terman JR, Mao T, Pastercamp RJ, Yu HH, Kolodkin AL. MICALs, a family of conserved flavoprotein oxidoreductases, function in plexin-mediated axonal repulsion. Cell. 2002; 109: 887-900.
26. Suzuki T, Nakamoto T, Ogawa S, Seo S, Matsumura T, Tachibana K, Morimoto C, Hirai H. MICAL, a novel CasL interacting molecule, associates with vimentin. J Biol Chem. 2002; 277: 14933-41.
27. Giordano S, Corso S, Conrotto P, Artigiani S, Gilestro G, Barberis D, Tamagnone L, Comoglio PM. The semaphorin 4D receptor controls invasive growth by coupling Met. Nat Cell Biol. 2002; 4: 720-4.
28. Luchino J, Hocine M, Amoureux MC, Gilbert B, Bernet A, Royet A, Treilleux I, Lécine P, Borg JP, Mehlen P, Chauvet S, Mann F. Semaphorin 3A suppress tumor cell death triggered by the Plexin D1 dependence receptor in metastatic breast cancers. Cancer Cell. 2013; 24: 673-85.
29. Zhou Y, Adolfs Y, Pijnappel WW, Fuller SJ, Van der Schors RC, Li KV, Sugden PH, Smit AB, Hergovich A, Pasterkamp RJ. MICAL-1 is a negative regulator of MSTNDR kinase signaling and apoptosis. Mol Cell Biol. 2011; 31: 3603-15.
30. Wallasch C, Weiss FU, Nierderfellner G, Jallal B, Issing W, Ullrich A. Heregulin-dependent regulation of HER2/ neu oncogenic signaling by heterodimerization with HER3. EMBO J. 1995; 14: 4267-75.
31. Folgiero V, Bacheleder RE. Bon G, Sacchi A, Falcioni R, Mercurio AM. The a6β4 can regulate ErbB-3 expression: implications for a6β4 signaling and function. Cancer Res. 2007; 67: 1645-52.
32. Balakrishnan A, Penachioni JY, Lamba S, Bleeker FE, Zanon C, Rodolfo M, Vallacchi V, Scarpa A, Felicioni L, Buck M, Marchetti A, Comoglio PM, Bardelli A, et al. Molecular profiling of the 'Plexisome' in melanoma and pancreatic cancer. Human Mutat. 2009; 30: 1167-1174.
33. Suzuki T, Nakamoto T, Ogawa S, Seo S, Matsumura T, Tachibana K, Morimoto C, Hirai H. MICAL, a novel CasL interacting molecule, associates with vimentin. J Biol Chem. 2002; 277: 14933-41.
34. Hung RJ, Terman JR. Extracellular inhibitors, repellents, and semaphorin/plexin/Mical-mediated actin filament disassembly. Cell. 2011; 68: 415-33.
35. Serirni G, Valdembri B, Zanivan S, Morterra G, Burkhardi C, Caccavari F, Zammataro R, Primo L, Tamagnone L, Logan M, Tessier-Lavigne M, Taniguchi M, Puschel A, et al. Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function. Nature. 2003; 424: 391-97.
36. Banu N, Teichman J, Dunlap-Brown M, Villegas G, Tufro A. Semaphorin 3C regulates endothelial cell function by increasing integrin activity. Faseb J. 2006; 20: 2150-52.
37. Prud'homme G, Glinka Y. Neuropilins are multifunctional coreceptors involved in tumor initiation, growth, metastasis and immunity. Oncotarget. 2012; 3: 921-939.
38. Giuffreda L, Del Bufalo D, Desideri M, Di Sanza C, Stoppacciaro A, Ricciardi MR, Chiaretti S, Tavolaro S, Benassi B, Bellacosa A, Foà R, Tafuri A, Cognetti F, et al. Therapeutic potential of PD0325901 in Melanoma. Neoplasia. 2009; 11: 720-31.
39. Suto F, Tsuboi M, Kamiya H, Mizuno H, Kiyama Y, Komai S, Shimizu M, Sanbo M, Yagi T, Hiromi Y, Chédotal A, Mitchell KJ, Manabe T, et al. Interactions between plexin-A2, plexin-A4, and semaphorin 6A control laminarestricted projection of hippocampal mossy fibers. Neuron. 2007; 53: 535-47.
40. Huber AB, Kolodkin AL, Ginty DD, Cloutier JF. Signaling at the growth cone: ligand-receptor complexes and the control of axon growth and guidance. Ann Rev Neurosci. 2003; 26: 509-62.
41. Tamagnone L. Emerging role of semaphorins as major regulatory signals and potential therapeutic targets in cancer. Cancer Cell. 2012; 22: 145-152.
42. Worzfeld T, Offermann S. Semaphorins and plexins as therapeutic targets. Nature Rev. 2014; 13: 603-621.
43. Daniotti M, Oggionni M, Ranzani T, Vallacchi V, Campi V, Di Stasi D, Torre GD, Perrone F, Luoni C, Suardi S, Frattini M, Pilotti S, Anichini A et al. BRAF alterations are associated with complex mutational profiles in malignant melanoma. Oncogene. 2004; 23: 5968-77.
44. Tassi E, Zanon M, Vegetti C, Molla A, Bersani I, Perotti V, Pennati M, Zaffaroni N, Milella M, Ferrone S, Carlo-Stella C, Gianni AM, Mortarini M, et al. Role of Apollon in human melanoma resistance to antitumor agents that activate the intrinsic or the extrinsic apoptosis pathways. Clin Cancer Res. 2012; 18: 3316-27.
45. Perotti V, Baldassari P, Bersani I, Molla A, Vegetti C, Tassi E, Dal Col J, Dolcetti R, Anichini A, Mortarini R. NFATc2 is a potential therapeutic target in human melanoma. J Invest Dermatol. 2012; 132: 2652-60
46. Anichini A, Mazzocchi A, Fossati G, Parmiani G. Cytotoxic T lymphocyte clones from peripheral blood and from tumor site detect intratumor heterogeneity of melanoma cells. Analysis of specificity and mechanims of interaction. J Immunol. 1989; 142: 3692-701.
47. Anichini A, Mortarini R, Supino R, Parmiani G. Human melanoma cells with high susceptibility to cell-mediated lysis can be identified on the basis of ICAM-1 phenotype, VLA profile and invasive ability. Int J Cancer 1990; 46: 508-15.
48. Castelli C, Sensi M, Lupetti R, Mortarini R, Panceri P, Anichini A, Parmiani G. Expression of interleukin 1 alpha, interleukin 6, and tumor necrosis factor alpha genes in human melanoma clones is associated with that of mutated N-RAS oncogene. Cancer Res 1994; 54: 4785-90.
49. Folgiero V, Avetrani A, Bon G, Di Carlo SE, Fabi A, Nisticò C, Vici P, Melucci E, Buglioni S, Perracchio L. Sperduti I, Rosanò L, Sacchi A, et al. Induction of ErbB-3 Expression by α6β4 Integrin Contributes to Tamoxifen Resistance in ERβ1-Negative Breast Carcinomas. PLoS ONE. 2008; 3: e1592.
50. Prislei S, Mozzetti T, Filippetti F, De Donato M, Raspaglio G, Cicchillitti L, Scambia G, Ferlini C. From plasma membrane to cytoskeleton: a novel function for Semaphorine 6A. Mol Cancer Ther. 2008; 7: 233-41.